Amgen buys cancer drugmaker for $10.4B

08/26/2013 | Reuters

Amgen agreed to acquire Onyx Pharmaceuticals for $125 per share, or around $10.4 billion, in the fifth-largest biotechnology deal ever. The agreement will give Amgen rights to several cancer drugs, including the multiple myeloma drug Kyprolis, liver and kidney cancer treatment Nexavar, and colon cancer drug Stivarga. The acquisition is expected to be finalized this year.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director Quality Improvement
Molina Healthcare of Texas
San Antonio, TX
Behavioral Health Medical Director
Network Health
Medford, MA
Senior Medical Director
Network Health
Medford, MA
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR